Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero
Alimentary Pharmacology & Therapeutics2021Vol. 55(6), pp. 700–704
Citations Over TimeTop 10% of 2021 papers
Emma Flanagan, Ralley Prentice, Emily K. Wright, Peter G. Gibson, Alyson L Ross, Jakob Begun, Miles Sparrow, Rimma Goldberg, Ourania Rosella, Megan Burns, Katerina Kiburg, Sally Bell
Abstract
Ustekinumab drug levels appear stable in pregnancy, with a delivery infant:maternal ratio similar to that of anti-TNFs. Infant ustekinumab clearance was complete by 20 weeks post-partum, however, infants exposed in utero should avoid live vaccination before 12 months of age until further clearance data are obtained.
Related Papers
- → Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis(2021)7 cited
- → Ustekinumab for the treatment of Crohn’s disease(2016)10 cited
- → A case report of heart failure after therapy with ustekinumab(2015)8 cited
- → Update on Ustekinumab for Psoriasis(2017)
- → 26440 Alternative uses of ustekinumab for nonindicated dermotologic conditions: A systematic review(2021)